PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy


A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.

Download the fact sheet.


Ages Eligible for Study:   12 months to 21 Years

Genders Eligible for Study:   Both

Accepts Healthy Volunteers:   No

Open and Recruiting

This study is currently recruiting participants.

Identifier: NCT02559778